ATE553189T1 - Immunokinasen - Google Patents

Immunokinasen

Info

Publication number
ATE553189T1
ATE553189T1 AT05716585T AT05716585T ATE553189T1 AT E553189 T1 ATE553189 T1 AT E553189T1 AT 05716585 T AT05716585 T AT 05716585T AT 05716585 T AT05716585 T AT 05716585T AT E553189 T1 ATE553189 T1 AT E553189T1
Authority
AT
Austria
Prior art keywords
component
complex
nucleic acid
acid molecules
diseases
Prior art date
Application number
AT05716585T
Other languages
English (en)
Inventor
Stefan Barth
Mehmet Kemal Tur
Michael Stoecker
Rainer Fischer
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Application granted granted Critical
Publication of ATE553189T1 publication Critical patent/ATE553189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05716585T 2004-01-16 2005-01-13 Immunokinasen ATE553189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04000847 2004-01-16
EP04017928 2004-07-29
PCT/EP2005/050131 WO2005068616A2 (en) 2004-01-16 2005-01-13 Immunokinases

Publications (1)

Publication Number Publication Date
ATE553189T1 true ATE553189T1 (de) 2012-04-15

Family

ID=34796697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716585T ATE553189T1 (de) 2004-01-16 2005-01-13 Immunokinasen

Country Status (6)

Country Link
US (1) US9045739B2 (de)
EP (1) EP1704228B1 (de)
AT (1) ATE553189T1 (de)
CA (1) CA2553261C (de)
ES (1) ES2384940T3 (de)
WO (1) WO2005068616A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
JP6243919B2 (ja) * 2012-10-24 2017-12-06 フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー． ファオ．Ｆｒａｕｎｈｏｆｅｒ−Ｇｅｓｅｌｌｓｃｈａｆｔ Ｚｕｒ Ｆｏｒｄｅｒｕｎｇ Ｄｅｒ Ａｎｇｅｗａｎｄｔｅｎ Ｆｏｒｓｃｈｕｎｇ Ｅ． Ｖ． 微小管修飾化合物
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP3836944A4 (de) * 2018-08-16 2022-05-11 Memorial Sloan Kettering Cancer Center Leucin-zipper-basierte zusammensetzungen und verfahren zur verwendung

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2078118C (en) * 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
US5439819A (en) * 1993-08-27 1995-08-08 The Regents Of The University Of California Chimeric protein tyrosine kinases
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
JP3317121B2 (ja) * 1996-01-25 2002-08-26 株式会社日立製作所 エバポシステムおよびその診断方法
US5935835A (en) * 1996-10-11 1999-08-10 Smithkline Beecham Corporation Polynucleotide encoding human Myt-1 kinase clone
CA2283636A1 (en) 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
US6346406B1 (en) * 1997-08-20 2002-02-12 University Of Medicine & Dentistry Of New Jersey Elongation factor-2 kinase (EF-2 kinase), and methods of use therefor
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
WO2001001137A1 (en) * 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
EP1272222A2 (de) * 2000-04-12 2003-01-08 Implyx Ltd. Zusammensetzung zur arzneimittelabgabe
ATE372130T1 (de) * 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20050176024A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
EP2415486B1 (de) 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Konjugate und Zusammensetzungen zur zellulären Verabreichung
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
EP1487995A4 (de) * 2002-02-13 2006-08-02 Medbridge Inc Proteinträgersystem für therapeutische oligonukleotide
EP1741781A3 (de) 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. Behandlung von Alzheimer-Krankheit durch RNA-Interferenz unter Verwendung von short interfering nucleic acid (siNA)
CN1717496A (zh) 2002-10-03 2006-01-04 洛桑生态综合技术联合公司 用o6－烷基鸟嘌呤－dna烷基转移酶标记蛋白
AU2003295389A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
EP1585756B1 (de) * 2002-11-26 2010-04-21 University of Massachusetts Verabreichung von sirnas
WO2004078215A2 (en) 2003-02-28 2004-09-16 The Board Of Trustees Of The University Of Illinois Use of antibody conjugated deoxycytidine kinase for adept
JP2007509608A (ja) 2003-05-23 2007-04-19 ウペエフエル・エコル・ポリテクニック・フェデラル・ドゥ・ローザンヌ アシル担体タンパク質に基づくタンパク質をラベルするための方法
WO2005044981A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
JP2007513968A (ja) 2003-12-12 2007-05-31 ウイスコンシン アラムニ リサーチ ファンデーション 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー
EP1730298B1 (de) 2004-03-02 2015-11-11 EPFL Ecole Polytechnique Fédérale de Lausanne Spezifische substrate für o6-alkylguanin-dna-alkyltransferase
EP1737879B1 (de) * 2004-04-19 2012-10-10 Archemix LLC Aptamer-vermittelte intrazelluläre verabreichung von therapeutischen oligonukleotiden
WO2006021553A1 (en) 2004-08-23 2006-03-02 Covalys Biosciences Ag Method for protein purification and labeling based on a chemoselective reaction
US8178314B2 (en) 2005-04-27 2012-05-15 Covalys Biosciences Ag Pyrimidines reacting with O6-alkylguanine-DNA alkyltransferase fusion protein and method for detecting protein
CA2628113A1 (en) 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP1882688A1 (de) 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Markierung von Fusionsproteinen mit synthetischen Proben

Also Published As

Publication number Publication date
EP1704228A2 (de) 2006-09-27
WO2005068616A2 (en) 2005-07-28
US9045739B2 (en) 2015-06-02
CA2553261C (en) 2014-03-18
EP1704228B1 (de) 2012-04-11
US20090136475A1 (en) 2009-05-28
ES2384940T3 (es) 2012-07-16
CA2553261A1 (en) 2005-07-28
WO2005068616A3 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2007044534A3 (en) Vegf analogs and methods of use
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EA201000146A1 (ru) Связующее майларда на основе гидроксимонокарбоновой кислоты
PH12012502215A1 (en) Anti-fgfr2 antibodies
WO2008047150A3 (en) Protein variants
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
EP2558478A4 (de) An 5 positionen modifizierte pyrimidine und ihre verwendung
MX350723B (es) Proteínas de unión a il-1.
AU2015213336B2 (en) Novel conjugates of CC-1065 analogs and bifunctional linkers
IL194438A (en) Diarrhylthiohydantoin Compounds, Pharmaceuticals Containing Them, Syntheses Methods and In Vitro Methods for Contacting them with Mammalian Cells
WO2007104062A3 (en) Compositions and methods based on peptide binding profiling
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
EP2361934A3 (de) Hepatozytenwachstumsfaktor (HGF) bindende Proteine
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
DOP2011000274A (es) Proteinas de union a il-17
WO2008089397A3 (en) Adrb2 cancer markers
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2005076999A3 (en) Methods and compositions for combination rnai therapeutics
WO2006044614A3 (en) Anti-angiogenic peptides and methods of use thereof
WO2011127070A3 (en) IRE-1α INHIBITORS
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof